SIMCERE PHARMA(02096)

Search documents
先声药业(02096.HK)拟不超5亿元回购股份
Ge Long Hui· 2025-08-21 13:34
格隆汇8月21日丨先声药业(02096.HK)公告,于2025年8月21日,董事会决议行使回购授权适时于公开市 场按不超过人民币5亿元的总金额回购股份。 ...
先声药业(02096)拟回购股份
智通财经网· 2025-08-21 13:33
于2025年8月21日,董事会决议行使回购授权适时于公开市场按不超过人民币5亿元的总金额回购股份。 董事会认为在现阶段回购股份能展现公司对其业务前景的信心,并终能为公司带来益处及为股东创造价 值。此外,董事会认为公司现时拥有的财务资源足以在维持稳健财务状况的同时进行建议股份回购。 智通财经APP讯,先声药业(02096)发布公告,根据股东于2025年6月13日举行的股东周年大会上通过的 股东决议案,公司董事获授予一般授权以回购最多2.47亿股公司股份,占截至2025年6月13日已发行股 份总数10%。 ...
先声药业拟回购股份
Zhi Tong Cai Jing· 2025-08-21 13:28
先声药业(02096)发布公告,根据股东于2025年6月13日举行的股东周年大会上通过的股东决议案,公司 董事获授予一般授权以回购最多2.47亿股公司股份,占截至2025年6月13日已发行股份总数10%。 于2025年8月21日,董事会决议行使回购授权适时于公开市场按不超过人民币5亿元的总金额回购股份。 董事会认为在现阶段回购股份能展现公司对其业务前景的信心,并终能为公司带来益处及为股东创造价 值。此外,董事会认为公司现时拥有的财务资源足以在维持稳健财务状况的同时进行建议股份回购。 ...
先声药业(02096) - 提名委员会职权范围
2025-08-21 13:23
Simcere Pharmaceutical Group Limited 先聲藥業集團有限公司 (於香港註冊成立的有限公司) (「本公司」) (股份代號:2096) 提名委員會職權範圍 (根據本公司董事會於2025年8月21日通過的決議案所採納) 目 標 1. 成 立 提 名 委 員 會 之 目 標 為 協 助 本 公 司 董 事(「董 事」)會(「董事會」)物 色、挑 選 及向董事會推薦適合成為本公司董事的人選,監督評定董事會表現的程序, 以及設計、向董事會推薦並監督本公司有關提名人選的指引。 成 員 – 1 – – 2 – 5. 提名委員會每年須至少召開一次會議及於必要情況下主席要求召開更多次 數會議。 6. 提名委員會會議須由公司秘書應主席之要求召開。 7. 就定期會議及在所有其他切實可行的情況下,議程及相關委員會文件應全部 送交提名委員會全體成員。該等文件應及時並於擬舉行會議日期最少三(3) 天 前(或 協 定 的 其 他 時 間 內)送 出。 8. 處理事務之必要法定人數須為兩(2)名成員,彼等均須為獨立非執行董事。委 員會會議按正當程序召開,而出席人數達法定數目的會議即具有足夠能力行 使提名委員會 ...
先声药业(02096) - 自愿公告 - 回购股份
2025-08-21 13:22
香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負 責,對其準確性或完整性亦不發表任何聲明,並明確表示,概不對因本公告全部 或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 Simcere Pharmaceutical Group Limited 先聲藥業集團有限公司 (於香港註冊成立的有限公司) (股份代號:2096) 自願公告 回購股份 根據股東於2025年6月13日舉行的股東週年大會上通過的股東決議案,本公司董事 (「董事」)獲授予一般授權以回購最多247,469,761股本公司股份(「股份」),佔截 至2025年6月13日已發行股份總數10%(「回購授權」)。 於2025年8月21日,董事會(「董事會」)決議行使回購授權適時於公開市場按不超 過人民幣 5 億元的總金額回購股份(「建議股份回購」)。建議股份回購的期間由 2025年8月22日起直至下列較早者為止:(a)本公司下屆股東週年大會的舉行日 期;(b)本公司根據本公司的組織章程細則或任何適用法例最遲須舉行下屆股東週 年大會的日期;或(c)股東於本公司股東大會上通過普通決議案撤銷或修訂有關授 權當日。本公司將利用 ...
先声药业(02096) - 2025 - 中期业绩
2025-08-21 13:20
香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責,對其準確性 或完整性亦不發表任何聲明,並明確表示,概不對因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 Simcere Pharmaceutical Group Limited 先聲藥業集團有限公司 (於香港註冊成立的有限公司) (股份代號:2096) 截 至2025年6月30日止六個月中期業績公告 財務摘要 截 至2025年6月30日止六個月,本集團錄得以下未經審核的財務業績: 1 為了對按照香港財務報告準則呈列的財務資料進行補充,本集團亦使用經調整歸屬於本公 司權益股東的利潤作為非香港財務報告準則指標,該指標屬於未經審核性質且並非香港財 務報告準則規定或根據香港財務報告準則呈列。 本集團將經調整歸屬於本公司權益股東的利潤界定為對下列項目作出調整的歸屬於本公司 權益股東的利潤:(i)以公允價值計量且其變動計入損益的金融資產的已變現及未變現虧損 淨額;(ii)以公允價值計量且其變動計入損益的聯營公司的已變現及未變現收益淨額;(iii)贖 回負債的利息費用;及(iv)上述項目的相關所得稅影響。 – 1 – ...
港股异动 | 先声药业(02096)涨近3% 旗下先声再明自研Polθ抑制剂SIM0508新获联用奥拉帕利临床批件
Zhi Tong Cai Jing· 2025-08-21 03:10
据介绍,SIM0508是抗肿瘤"合成致死"机制的最新成果,由先声再明自主研发,也是中国首个获批进入 临床研究的Polθ抑制剂。SIM0508已取得中美两国IND批件,目前处于临床I期。早期临床研究显示, SIM0508安全性和耐受性良好,未观察到明显的血液学毒性,提示其与PARP抑制剂或化疗药物联用产 生的叠加血液毒性风险较低,有潜力成为一款治疗多种HRD实体瘤的创新抗癌疗法。其相关研究数据 将在未来的学术年会中公布。 消息面上,据先声药业官微消息,集团旗下抗肿瘤创新药公司先声再明宣布,其自主研发的抗肿瘤候选 药物——DNA聚合酶θ(Polθ)小分子抑制剂SIM0508已获得国家药品监督管理局(NMPA)批准,联合奥拉 帕利开展治疗晚期实体瘤的临床试验。 智通财经APP获悉,先声药业(02096)涨近3%,截至发稿,涨2.58%,报12.7港元,成交额5562.95万港 元。 ...
先声药业涨近3% 旗下先声再明自研Polθ抑制剂SIM0508新获联用奥拉帕利临床批件
Zhi Tong Cai Jing· 2025-08-21 03:04
Core Viewpoint - Xiansheng Pharmaceutical (02096) has seen a nearly 3% increase in stock price following the announcement of its innovative anti-tumor drug candidate SIM0508 receiving approval from the National Medical Products Administration (NMPA) for clinical trials in combination with Olaparib for the treatment of advanced solid tumors [1] Company Summary - Xiansheng Pharmaceutical's subsidiary, Xiansheng Zaiming, announced that its self-developed anti-tumor candidate drug, DNA polymerase theta (Polθ) small molecule inhibitor SIM0508, has been approved for clinical trials [1] - SIM0508 is the first Polθ inhibitor approved for clinical research in China and has also received IND approvals in both China and the United States, currently in Phase I clinical trials [1] - Early clinical studies indicate that SIM0508 has good safety and tolerability, with no significant hematological toxicity observed, suggesting a low risk of additive hematological toxicity when used in combination with PARP inhibitors or chemotherapy drugs [1] Industry Summary - The approval of SIM0508 represents a significant advancement in the "synthetic lethality" mechanism for anti-tumor therapies, highlighting the potential for innovative cancer treatments targeting various homologous recombination deficiency (HRD) solid tumors [1] - Relevant research data regarding SIM0508 will be presented at upcoming academic conferences, indicating ongoing developments in the field of oncology [1]
研判2025!中国结直肠癌(CRC)药物行业发展背景、市场现状及未来趋势分析:结直肠癌患者数量庞大,对相关药物需求旺盛,带动市场规模迅速增长[图]
Chan Ye Xin Xi Wang· 2025-08-20 01:19
Core Insights - Colorectal cancer (CRC) is the second most common malignant tumor in China, with 517,100 new cases in 2022, accounting for 10.7% of all cancer cases, and 240,000 deaths, representing 9.3% of all cancer deaths [1][12] - The global colorectal cancer drug market is projected to grow from $16.9 billion in 2019 to $25.4 billion by 2024, indicating significant market potential [1][13] - The Chinese colorectal cancer drug market is expected to reach 24.21 billion yuan by 2024, with an 18.5% year-on-year growth [1][16] - The market is characterized by a competitive landscape with multiple companies across different tiers, including leading firms like Junshi Biosciences and others [1][18] Industry Overview - Colorectal cancer drugs include traditional chemotherapy, targeted therapies, and immunotherapies, which are crucial for extending patient survival [2] - The burden of colorectal cancer in China is significant, with over 80% of patients diagnosed at advanced stages, leading to high treatment demands [1][16] - The market is expected to continue growing, with projections of 37.3 billion yuan by 2027 and nearly 60 billion yuan by 2031 [1][20] Competitive Landscape - The colorectal cancer drug industry features a tiered structure: - First tier: Junshi Biosciences - Second tier: Maibao Pharmaceutical, Hutchison China MediTech - Third tier: JAKS Pharmaceuticals, Jinfang Pharmaceutical [1][18] - Over 10 innovative therapies have been approved globally for colorectal cancer treatment, with more in clinical trials [1][18] Future Trends - The market is expected to see a shift towards precision medicine, with targeted and immunotherapies becoming mainstream [1][22] - Domestic innovative pharmaceutical companies are rapidly emerging, enhancing their product lines through independent research and global collaborations [1][23] - Upgraded patient needs will drive innovations in service models, focusing on unmet clinical demands and improving treatment experiences [1][25]
先声药业(02096):更新报告:创新验证,商业放量,看好重估
ZHESHANG SECURITIES· 2025-08-18 08:57
Investment Rating - The investment rating for the company is "Buy" (maintained) [5] Core Views - The company's licensing agreement with AbbVie for SIM0500 demonstrates the strength of its innovative technology platform, which is expected to lead to a revaluation of the company [2][5] - The company is anticipated to exceed expectations in pipeline progress, business development (BD) collaborations, and revenue growth [1][2] Summary by Sections Innovation and Business Development - The company signed a licensing agreement with AbbVie on January 13, 2025, for the investigational drug SIM0500, which could yield up to $1.055 billion in payments [2] - The company is also collaborating with NextCure to develop SIM0505, with potential payments of up to $745 million [2] - The first patient in the U.S. received SIM0500 in a Phase I clinical trial, with promising data from similar trials by competitors [2] Commercialization - The company's innovative drug revenue is projected to reach 4.928 billion yuan in 2024, accounting for 74.3% of total revenue [3] - New products are expected to drive revenue growth, with several drugs successfully included in the National Reimbursement Drug List (NRDL) [3] Catalysts and Indicators - Key indicators include the revenue growth of innovative drug products, clinical data readouts for SIM0500, and progress in overseas development of the sublingual formulation [4] - Catalysts for growth include exceeding expectations in clinical advancements and BD collaborations [4] Financial Forecast and Valuation - Revenue projections for 2025-2027 are 7.735 billion, 8.769 billion, and 9.882 billion yuan, with year-on-year growth rates of 17%, 13%, and 13% respectively [5][12] - Net profit forecasts for the same period are 1.071 billion, 1.375 billion, and 1.577 billion yuan, with growth rates of 46%, 28%, and 15% respectively [5][12]